000154752 001__ 154752
000154752 005__ 20240322115503.0
000154752 0247_ $$2pmid$$apmid:33399945
000154752 0247_ $$2doi$$a10.1007/s00401-020-02255-2
000154752 0247_ $$2ISSN$$a0001-6322
000154752 0247_ $$2ISSN$$a1432-0533
000154752 0247_ $$2altmetric$$aaltmetric:97111815
000154752 0247_ $$2pmid$$a33399945
000154752 0247_ $$2pmc$$apmc:PMC7847437
000154752 037__ $$aDZNE-2021-00342
000154752 082__ $$a610
000154752 1001_ $$00000-0003-1636-1700$$aAttems, Johannes$$b0
000154752 245__ $$aNeuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study
000154752 260__ $$aHeidelberg$$bSpringer$$c2021
000154752 3367_ $$2DRIVER$$aarticle
000154752 3367_ $$2DataCite$$aOutput Types/Journal article
000154752 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711023726_32505
000154752 3367_ $$2BibTeX$$aARTICLE
000154752 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154752 3367_ $$00$$2EndNote$$aJournal Article
000154752 520__ $$aCurrently, the neuropathological diagnosis of Lewy body disease (LBD) may be stated according to several staging systems, which include the Braak Lewy body stages (Braak), the consensus criteria by McKeith and colleagues (McKeith), the modified McKeith system by Leverenz and colleagues (Leverenz), and the Unified Staging System by Beach and colleagues (Beach). All of these systems use semi-quantitative scoring (4- or 5-tier scales) of Lewy pathology (LP; i.e., Lewy bodies and Lewy neurites) in defined cortical and subcortical areas. While these systems are widely used, some suffer from low inter-rater reliability and/or an inability to unequivocally classify all cases with LP. To address these limitations, we devised a new system, the LP consensus criteria (LPC), which is based on the McKeith system, but applies a dichotomous approach for the scoring of LP (i.e., "absent" vs. "present") and includes amygdala-predominant and olfactory-only stages. α-Synuclein-stained slides from brainstem, limbic system, neocortex, and olfactory bulb from a total of 34 cases with LP provided by the Newcastle Brain Tissue Resource (NBTR) and the University of Pennsylvania brain bank (UPBB) were scanned and assessed by 16 raters, who provided diagnostic categories for each case according to Braak, McKeith, Leverenz, Beach, and LPC systems. In addition, using LP scores available from neuropathological reports of LP cases from UPBB (n = 202) and NBTR (n = 134), JT (UPBB) and JA (NBTR) assigned categories according to all staging systems to these cases. McKeith, Leverenz, and LPC systems reached good (Krippendorff's α ≈ 0.6), while both Braak and Beach systems had lower (Krippendorff's α ≈ 0.4) inter-rater reliability, respectively. Using the LPC system, all cases could be unequivocally classified by the majority of raters, which was also seen for 97.1% when the Beach system was used. However, a considerable proportion of cases could not be classified when using Leverenz (11.8%), McKeith (26.5%), or Braak (29.4%) systems. The category of neocortical LP according to the LPC system was associated with a 5.9 OR (p < 0.0001) of dementia in the 134 NBTR cases and a 3.14 OR (p = 0.0001) in the 202 UPBB cases. We established that the LPC system has good reproducibility and allows classification of all cases into distinct categories. We expect that it will be reliable and useful in routine diagnostic practice and, therefore, suggest that it should be the standard future approach for the basic post-mortem evaluation of LP.
000154752 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000154752 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000154752 650_2 $$2MeSH$$aAutopsy
000154752 650_2 $$2MeSH$$aBrain: pathology
000154752 650_2 $$2MeSH$$aBrain Mapping
000154752 650_2 $$2MeSH$$aConsensus
000154752 650_2 $$2MeSH$$aHumans
000154752 650_2 $$2MeSH$$aLewy Bodies: pathology
000154752 650_2 $$2MeSH$$aLewy Body Disease: classification
000154752 650_2 $$2MeSH$$aLewy Body Disease: diagnosis
000154752 650_2 $$2MeSH$$aLewy Body Disease: pathology
000154752 650_2 $$2MeSH$$aObserver Variation
000154752 650_2 $$2MeSH$$aReproducibility of Results
000154752 7001_ $$aToledo, Jon B.$$b1
000154752 7001_ $$aWalker, Lauren$$b2
000154752 7001_ $$aGelpi, Ellen$$b3
000154752 7001_ $$aGentleman, Steve$$b4
000154752 7001_ $$aHalliday, Glenda$$b5
000154752 7001_ $$aHortobagyi, Tibor$$b6
000154752 7001_ $$aJellinger, Kurt$$b7
000154752 7001_ $$aKovacs, Gabor G.$$b8
000154752 7001_ $$aLee, Edward B.$$b9
000154752 7001_ $$aLove, Seth$$b10
000154752 7001_ $$aMcAleese, Kirsty E.$$b11
000154752 7001_ $$aNelson, Peter T.$$b12
000154752 7001_ $$0P:(DE-2719)2810592$$aNeumann, Manuela$$b13
000154752 7001_ $$aParkkinen, Laura$$b14
000154752 7001_ $$aPolvikoski, Tuomo$$b15
000154752 7001_ $$aSikorska, Beata$$b16
000154752 7001_ $$aSmith, Colin$$b17
000154752 7001_ $$aGrinberg, Lea Tenenholz$$b18
000154752 7001_ $$aThal, Dietmar R.$$b19
000154752 7001_ $$0P:(DE-HGF)0$$aTrojanowski, John Q.$$b20
000154752 7001_ $$aMcKeith, Ian G.$$b21
000154752 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-020-02255-2$$gVol. 141, no. 2, p. 159 - 172$$n2$$p159 - 172$$tActa neuropathologica$$v141$$x1432-0533$$y2021
000154752 8564_ $$uhttps://pub.dzne.de/record/154752/files/DZNE-2021-00342.pdf$$yOpenAccess
000154752 8564_ $$uhttps://pub.dzne.de/record/154752/files/DZNE-2021-00342.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154752 909CO $$ooai:pub.dzne.de:154752$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000154752 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810592$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000154752 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000154752 9130_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000154752 9141_ $$y2021
000154752 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000154752 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000154752 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bACTA NEUROPATHOL : 2021$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2021$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000154752 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-29$$wger
000154752 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154752 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000154752 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000154752 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000154752 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000154752 920__ $$lyes
000154752 9201_ $$0I:(DE-2719)1210003$$kAG Neumann$$lMolecular Neuropathology of Neurodegenerative Diseases$$x0
000154752 980__ $$ajournal
000154752 980__ $$aVDB
000154752 980__ $$aUNRESTRICTED
000154752 980__ $$aI:(DE-2719)1210003
000154752 9801_ $$aFullTexts